PMC7204851_01
The patient's clinical course. Nilotinib administration had an adverse effect on white blood cell and platelets, but did not diminish the bcr-abl fusion gene. The switch to bosutinib and dasatinib therapy did not change the response. The patient responded only to ponatinib treatment, which achieved a hematological response with 18% of bcr-abl1 FISH. However, no durable response was available. Hematopoietic stem cell transplantation yielded a molecular response without detection of major BCR-ABL1 mRNA by RT-PCR. The patient died of transplantation-related mortality, GVHD and TMA on the 121st day after transplantation. FISH, fluorescence in situ hybridization; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; PLT, platelet; TMA, thrombotic microangiopathy; WBC, white blood cells.
cro-0013-0449-g01.jpg
PMC7204851_01_cro-0013-0449-g01.jpg
F1
None of the TKIs exerted a clinical response, except for ponatinib, which yielded a hematological response (Fig. 1).